Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Shares of Hims & Hers Health (NYSE: HIMS) have been on fire over the past year, but they're not expensive by most valuation ...

Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Last week, Hims & Hers Health (NYSE:HIMS) dropped another mic with its latest earnings, and the numbers are mind-blowing.

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $23.41 which represents a decrease of $-0.21 or -0.89% from the prior close of $23.62. The stock opened at $23.6 and ...

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...